PARP1 and ovarian carcinoma: Taking advantage of the intrinsic tumor-targeting feature of EVs, S.M. Kim et al. used tumor cell-derived EVs to deliver CRISPR/Cas9 plasmids targeting poly(ADP-ribose) polymerase-1 (PARP-1) for ovarian cancer therapy [103].